Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 276

1.

Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings.

Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S49-56. doi: 10.1093/infdis/jit107. Review.

2.

Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.

De Luca A, Hamers RL, Schapiro JM.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S63-9. doi: 10.1093/infdis/jit109. Review.

4.

Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.

van Zyl GU, van der Merwe L, Claassen M, Zeier M, Preiser W.

J Med Virol. 2011 Oct;83(10):1764-9. doi: 10.1002/jmv.22189.

PMID:
21837793
5.

HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Siangphoe U, Suwanlerk T, Ananworanich J; HIV-NAT 086Study Team..

HIV Med. 2010 Oct 1;11(9):565-72. doi: 10.1111/j.1468-1293.2010.00828.x.

6.

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.

Clin Infect Dis. 2007 Feb 1;44(3):447-52.

7.

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.

Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, Fiscus SA, Nelson JA, Eron JJ, Kumwenda J.

AIDS. 2009 Jun 1;23(9):1127-34. doi: 10.1097/QAD.0b013e32832ac34e.

8.

Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.

Crawford KW, Wakabi S, Kibuuka H, Magala F, Keshinro B, Okoye I, Akintunde E, Hamm TE.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):796-9. doi: 10.1089/AID.2013.0294.

PMID:
24798614
9.

High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines.

Kebe K, Thiam M, Diagne Gueye NR, Diop H, Dia A, Signate Sy H, Charpentier C, Belec L, Mboup S, Toure Kane C.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):242-9. doi: 10.1089/aid.2011.0300.

PMID:
22860571
10.

Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.

Aghokeng AF, Kouanfack C, Eymard-Duvernay S, Butel C, Edoul GE, Laurent C, Koulla-Shiro S, Delaporte E, Mpoudi-Ngole E, Peeters M.

J Int AIDS Soc. 2013 Jan 31;16:18004. doi: 10.7448/IAS.16.1.18004.

11.

Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy.

Etiebet MA, Shepherd J, Nowak RG, Charurat M, Chang H, Ajayi S, Elegba O, Ndembi N, Abimiku A, Carr JK, Eyzaguirre LM, Blattner WA.

AIDS. 2013 Feb 20;27(4):553-61. doi: 10.1097/QAD.0b013e32835b0f59.

PMID:
23079810
12.

Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.

Barth RE, Aitken SC, Tempelman H, Geelen SP, van Bussel EM, Hoepelman AI, Schuurman R, Wensing AM.

Antivir Ther. 2012;17(2):377-86. doi: 10.3851/IMP2010.

PMID:
22297391
13.

Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.

Meresse M, March L, Kouanfack C, Bonono RC, Boyer S, Laborde-Balen G, Aghokeng A, Suzan-Monti M, Delaporte E, Spire B, Carrieri MP, Laurent C; Stratall ANRS 12110/ESTHER Study Group..

HIV Med. 2014 Sep;15(8):478-87. doi: 10.1111/hiv.12140.

14.

Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.

Mulu A, Maier M, Liebert UG.

PLoS One. 2015 Oct 29;10(10):e0141318. doi: 10.1371/journal.pone.0141318.

15.

HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients.

Elmi Abar A, Jlizi A, Darar HY, Kacem MA, Slim A.

Diagn Pathol. 2012 Oct 8;7:138. doi: 10.1186/1746-1596-7-138.

16.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
17.

Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.

Musiime V, Kaudha E, Kayiwa J, Mirembe G, Odera M, Kizito H, Nankya I, Ssali F, Kityo C, Colebunders R, Mugyenyi P.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):449-55. doi: 10.1089/aid.2012.0283.

PMID:
23308370
18.

Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.

Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Stevens WS, Rinke de Wit TF, Schuurman R; PharmAccess African Studies to Evaluate Resistance (PASER)..

Clin Infect Dis. 2012 Jun;54(11):1660-9. doi: 10.1093/cid/cis254.

19.
20.

HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S.

Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):83-8.

PMID:
19323038
Items per page

Supplemental Content

Support Center